var data={"title":"Thioguanine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Thioguanine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7042?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=thioguanine-drug-information\" class=\"drug drug_general\">see &quot;Thioguanine: Drug information&quot;</a> and <a href=\"topic.htm?path=thioguanine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Thioguanine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226912\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tabloid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226913\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lanvis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050255\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite (Purine Analog)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050247\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=thioguanine-drug-information\" class=\"drug drug_general\">see &quot;Thioguanine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Refer to individual protocols for dosing, and frequency; dosing presented as mg/m<sup>2</sup> and mg/kg; use extra precaution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphoblastic leukemia (ALL): </b>Limited data available: Delayed intensification treatment phase: Children &ge;1 year and Adolescents: Oral: 60 mg/m<sup>2</sup>/dose once daily for 14 days (Lange 2002; Nachman 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants, Children, and Adolescents: Oral: 2 mg/<b>kg</b> once daily for 4 weeks; if no clinical improvement after 4 weeks and ANC and platelet counts are not depressed, may increase dose to 3 mg/kg once daily with careful monitoring</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available (Lange 1998): DCTER regimen: Induction:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;3 years: Oral: 3.3 mg/<b>kg</b>/day divided once or twice daily for 4 days in combination with cytarabine and daunorubicin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;3 years and Adolescents: Oral: 100 mg/m<sup>2</sup>/day divided once or twice daily for 4 days in combination with cytarabine and daunorubicin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) with Down syndrome: </b>Limited data available: DCTER regimen: Induction:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;3 years: Oral: 3.3 mg/<b>kg</b>/day divided once or twice daily for 4 days in combination with cytarabine and daunorubicin (Lange 1998; Sorrell 2012; Wood 1993; Gamis 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;3 years and Adolescents: Oral: 100 mg/m<sup>2</sup>/day divided once or twice daily for 4 days in combination with cytarabine and daunorubicin (Sorrell 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS Tumors, low grade gliomas: </b>Limited data available (Ater 2012): TPCV regimen: Children &lt;10 years: Oral: 30 mg/m<sup>2</sup> every 6 hours x 11 doses (from hours 0 to 66) in a 42-day cycle for a total of 8 cycles (in combination with procarbazine, lomustine, and vincristine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Acute myeloid leukemia (AML):</b> Oral: 2 mg/kg once daily for 4 weeks; if no clinical improvement after 4 weeks and ANC and platelet counts are not depressed, may increase dose to 3 mg/kg once daily with careful monitoring</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b>  There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; some suggest that no adjustment required in pediatric patients (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling for patients with baseline hepatic impairment. For hepatotoxicity during treatment (eg, deterioration in transaminases, alkaline phosphatase or bilirubin, toxic hepatitis, biliary stasis, clinical jaundice, evidence of hepatic sinusoidal obstruction syndrome (veno-occlusive disease), or evidence of portal hypertension: Discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226891\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tabloid: 40 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226876\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050259\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Total daily dose may be administered at one time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132839\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226907\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050258\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Remission induction and remission consolidation treatment of acute nonlymphocytic leukemia (ANLL, AML) [FDA approved in pediatrics (age not specified) and adults]; has also been used for treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia or myelodysplastic syndrome in individuals with Down syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F853383\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Thioguanine may be confused with thiotepa</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">6-thioguanine and 6-TG are error-prone abbreviations (associated with sixfold overdoses of thioguanine)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lanvis [Canada and multiple international markets] may be confused with Lantus brand name for insulin glargine [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226954\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Esophageal varices, portal hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Fluid retention, hyperuricemia (common), weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, intestinal necrosis, intestinal perforation, nausea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (may be delayed), bone marrow hypoplasia, granulocytopenia, hemorrhage, leukopenia (common; may be delayed), pancytopenia, splenomegaly, thrombocytopenia (common; may be delayed)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Ascites, hepatic necrosis (centrilobular), hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatitis, hepatomegaly (tender), hepatotoxicity, hyperbilirubinemia, increased liver enzymes, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226897\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;display:inline\">Prior resistance to thioguanine (or mercaptopurine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to thioguanine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226880\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Myelosuppression (anemia, leukopenia, and/or thrombocytopenia) is a common dose-related toxicity (may be delayed); monitor for infection (due to leukopenia) or bleeding (due to thrombocytopenia); withhold treatment with abnormally significant drop in blood counts. Patients with genetic enzyme deficiency of thiopurine methyltransferase (TPMT) or who are receiving drugs which inhibit this enzyme (mesalazine, olsalazine, sulfasalazine) may be highly sensitive to myelosuppressive effects and may require substantial dose reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Long-term continuous therapy or maintenance treatment is associated with a high risk for hepatotoxicity, hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), or portal hypertension. Monitor liver function carefully for liver toxicity and discontinue in patients with evidence of hepatotoxicity, hepatic SOS (eg, hyperbilirubinemia, hepatomegaly [tender], and weight gain due to ascites and fluid retention) or portal hypertension (eg, splenomegaly, thrombocytopenia, esophageal varices). Hepatotoxicity with or without transaminase elevations may occur. Pathologic findings of hepatotoxicity include hepatoportal sclerosis, idiopathic noncirrhotic portal hypertension (including nodular regenerative hyperplasia), peliosis hepatitis, and periportal fibrosis. Hepatotoxicity may be more prevalent in male patients. Long-term/maintenance treatment with thioguanine is not recommended. Advise patients to avoid alcohol; may increase the risk for hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Thioguanine is potentially carcinogenic.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Hyperuricemia occurs commonly with treatment; institute adequate hydration and prophylactic allopurinol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thiopurine methyltransferase deficiency: Patients with genetic enzyme deficiency of thiopurine methyltransferase (TPMT) may be sensitive to myelosuppressive effects. May require substantial dose reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not recommended for maintenance therapy or long term continuous treatment due to toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cross resistance: Cross resistance with mercaptopurine generally occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Avoid vaccination with live vaccines during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25955840\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Liver toxicity is particularly prevalent in children (up to 25%) receiving maintenance therapy for acute lymphoblastic leukemia and in males.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300132\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226885\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12835&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May decrease the metabolism of Thiopurine Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased.<b> Exceptions: </b>Lenalidomide; Pomalidomide; Thalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226887\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10329862\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050254\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, liver function tests (serum transaminases, alkaline phosphatase, bilirubin), hemoglobin, hematocrit, serum uric acid; testing for thiopurine methyltransferase (TPMT) deficiency is available; clinical signs of portal hypertension or hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226879\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Purine analog that is incorporated into DNA and RNA resulting in the blockage of synthesis and metabolism of purine nucleotides</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226896\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: ~30% (range: 14% to 46%; highly variable)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Does not reach therapeutic concentrations in the CSF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; rapidly and extensively via thiopurine methyltransferase (TPMT) to 2-amino-6-methylthioguanine (MTG; active) and inactive compounds</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 5 to 9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Within 8 hours; predominantly metabolite(s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine, primarily as metabolites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226895\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">\n      <b>20 mg/mL (ASHP Standard Concentration) (ASHP 2017)</b></p>\n    <p style=\"text-indent:0em;\">A 20 mg/mL oral suspension may be prepared in a vertical flow hood with tablets and Ora-Plus and Ora-Sweet <b>or </b>methylcellulose 1% and simple syrup (Aliabadi 2011).</p>\n    <p style=\"text-indent:0em;\">\n      <i>Ora-Plus and Ora-Sweet:</i> Crush fifteen 40 mg thioguanine tablets in a mortar and reduce to a fine powder. Add 5 mL of Ora-Plus in incremental proportions and mix to a uniform paste. Transfer to a graduated amber glass bottle, rinse mortar with Ora-Sweet and add sufficient quantity to make 30 mL. Label &quot;shake well.&quot; Stable for 63 days at room temperature.</p>\n    <p style=\"text-indent:0em;\">\n      <i>Methylcellulose and simple syrup: </i>Crush fifteen 40 mg thioguanine tablets in a mortar and reduce to a fine powder. Add 3.33 mL of methylcellulose 1% in incremental proportions and mix to a uniform paste. Transfer to a graduated amber glass bottle, rinse mortar with simple syrup and add sufficient quantity to make 30 mL. Label &quot;shake well.&quot; Stable for 63 days at room temperature.</p>\n    <div class=\"reference\">Aliabadi HM, Romanick M, Somayaji V, Mahdipoor P, Lavasanifar A. Stability of compounded thioguanine oral suspensions [published correction appears in <i>Am J Health Syst Pharm.</i> 2011;68(14):1278.]. <i>Am J Health Syst Pharm.</i> 2011;68(10):900-908.<span class=\"pubmed-id\">21546641</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226899\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tabloid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (25): $758.32</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038839\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>6-TG (IN);</li>\n      <li>Lanvis (AE, AR, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CY, CZ, EE, EG, ET, FR, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, IE, IL, IQ, IR, JM, JO, KE, KR, KW, LB, LR, LT, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PL, QA, SA, SC, SD, SE, SI, SK, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Tabloid (UY);</li>\n      <li>Thioguanin Glaxo Wellcome (AT, DE);</li>\n      <li>Thioguanine Wellcome (IT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians, 2007, 173.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broxson EH, Dole M, Wong R, et al, &ldquo;Portal Hypertension Develops in a Subset of Children With Standard Risk Acute Lymphoblastic Leukemia Treated With Oral 6-Thioguanine During Maintenance Therapy,&rdquo; <i>Pediatr Blood Cancer</i>, 2005, 44(3):226-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/15503293 /pubmed\" target=\"_blank\" id=\"15503293 \">15503293 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Culbert SJ, Shuster JJ, Land VJ, et al, &ldquo;Remission Induction and Continuation Therapy in Children With Their First Relapse of Acute Lymphoid Leukemia: A Pediatric Oncology Group Study,&rdquo; <i>Cancer</i>, 1991, 67(1):37-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/1985721/pubmed\" target=\"_blank\" id=\"1985721\">1985721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lange BJ, Bostrom BC, Cherlow JM, et al, &quot;Double-Delayed Intensification Improves Event-Free Survival for Children With Intermediate-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group,&quot; <i>Blood</i>, 2002, 99(3):825-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/11806983/pubmed\" target=\"_blank\" id=\"11806983\">11806983</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. <i>Blood</i>. 1998;91(2):608-615.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/9427716/pubmed\" target=\"_blank\" id=\"9427716\">9427716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nachman JB, Sather HN, Sensel MG, et al, &quot;Augmented Post-Induction Therapy for Children With High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy,&quot; <i>N Engl J Med</i>, 1998, 338(23):1663-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/9614257/pubmed\" target=\"_blank\" id=\"9614257\">9614257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. <i>J Clin Oncol</i>. 1991;9(4):572-580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/2066754/pubmed\" target=\"_blank\" id=\"2066754\">2066754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorrell AD, Alonzo TA, Hilden JM, et al. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. <i>Cancer</i>. 2012;118(19):4806-4814.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/22392565/pubmed\" target=\"_blank\" id=\"22392565\">22392565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steuber CP, Civin C, Krischer J, et al, &ldquo;A Comparison of Induction and Maintenance Therapy for Acute Nonlymphocytic Leukemia in Childhood: Results of a Pediatric Oncology Group Study,&rdquo; <i>J Clin Oncol</i>, 1991, 9(2):247-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/1988573 /pubmed\" target=\"_blank\" id=\"1988573 \">1988573 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stork LC, Matloub Y, Broxson E, et al, &quot;Oral 6-Mercaptopurine Versus Oral 6-Thioguanine and Veno-occlusive Disease in Children With Standard-Risk Acute Lymphoblastic Leukemia: Report of the Children's Oncology Group CCG-1952 Clinical Trial,&quot; <i>Blood</i>, 2010, 115(14):2740-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/20124218/pubmed\" target=\"_blank\" id=\"20124218\">20124218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vora A, Mitchell CD, Lennard L, et al, &quot;Toxicity and Efficacy of 6-Thioguanine Versus 6-Mercaptopurine in Childhood Lymphoblastic Leukaemia: A Randomised Trial,&quot; <i>Lancet</i>, 2006, 368(9544):1339-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/17046466/pubmed\" target=\"_blank\" id=\"17046466\">17046466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. <i>Cancer</i>. 1990;66(6):1106-1113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thioguanine-pediatric-drug-information/abstract-text/2205352/pubmed\" target=\"_blank\" id=\"2205352\">2205352</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12835 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F226912\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F226913\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050255\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050247\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F226891\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F226876\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050259\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132839\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F226907\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050258\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F853383\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F226954\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F226897\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F226880\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25955840\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300132\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F226885\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F226887\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10329862\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050254\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F226879\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F226896\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F226895\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F226899\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038839\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12835|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=thioguanine-drug-information\" class=\"drug drug_general\">Thioguanine: Drug information</a></li><li><a href=\"topic.htm?path=thioguanine-patient-drug-information\" class=\"drug drug_patient\">Thioguanine: Patient drug information</a></li></ul></div></div>","javascript":null}